Blueprint Medicines Corporation (BPMC)

Compare

85.94

-2.57

(-2.90%)

At close: April 1 at 4:00:01 PM EDT

85.42

-0.52

(-0.61%)

Pre-Market: 4:49:29 AM EDT

Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that company management will participate virtually in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 12:45 p.m. ET.

PR Newswire yesterday

BPMC
-2.90%
Is Blueprint Medicines (BPMC) One of the Best Mid Cap Biotech Stocks to Buy?

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against the other best mid cap biotech stocks to buy. Is the Biotech Sector Oversaturated? On March 6, Jared Holz, Mizuho health care […]

Insider Monkey 2 days ago

BPMC
-2.90%
Is Blueprint Medicines Corporation (BPMC) a Promising Biotech Stock According to Wall Street Analysts

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other biotech stocks. Biotech Sector Set for Growth Amid Innovation and Investor Interest The biotechnology sector is gaining new momentum with better market […]

Insider Monkey 7 days ago

BPMC
-2.90%
Blueprint Medicines (BPMC): Among Stocks Insiders Are Selling In March

We recently published a list of 10 Stocks Insiders Are Selling In March. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other stocks Insiders are selling in March. Wall Street experienced a challenging week, marked by turbulence as the broader market entered a correction, declining […]

Insider Monkey 12 days ago

BPMC
-2.90%
Reddit initiated, Netflix upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: MoffettNathanson upgraded Netflix (NFLX) to Buy from Neutral with a price target of $1,100, up from $850. The firm believes the company’s ability to monetize its engagement remains underappreciated. William Blair upgraded DocuSign (DOCU) to Outperform from Market Perform. The firm is bullish on the mar

TipRanks 14 days ago

EMR

NFLX

CION
Exploring High Growth Tech Stocks In The US Market March 2025

Over the last 7 days, the United States market has dropped 4.4%, yet it remains up by 7.5% over the past year, with earnings projected to grow by 14% annually. In this context of fluctuating performance and optimistic earnings forecasts, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to changing market dynamics.

Simply Wall St. 19 days ago

CYBR

RZLV

RZLVW
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting its ongoing efforts to innovate the treatment of mast cell-driven diseases. The presentations include three-year median follow-up data from the registrational PIONEER trial demonstrating the strong long-term efficacy and safety of AYVAKIT® (avapritinib) in patients with indolent systemic mastocytosis (ISM), and real-world evidence further characterizing the substantial burden of the disease, highlighting

PR Newswire last month

BPMC
-2.90%
Blueprint Medicines Corporation (BPMC): Among the Oversold Biotech Stocks to Buy Now

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other oversold biotech stocks to buy now. Biotech Sector Performance and Challenges in 2024: Biotechnology stocks are among the most volatile in the market, […]

Insider Monkey last month

BPMC
-2.90%
Blueprint Medicines Full Year 2024 Earnings: EPS Beats Expectations

Blueprint Medicines ( NASDAQ:BPMC ) Full Year 2024 Results Key Financial Results Revenue: US$508.8m (up 104% from FY...

Simply Wall St. last month

BPMC
-2.90%
BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline

Blueprint Medicines' fourth-quarter earnings and sales miss estimates. Shares of the company decline following the announcement.

Zacks last month

BPMC
-2.90%
Blueprint Medicines Corp (BPMC) Q4 2024 Earnings Call Highlights: Record Growth and Strategic ...

Blueprint Medicines Corp (BPMC) reports a 135% revenue surge for AYVAKIT, outlines ambitious growth plans for 2025 amidst market challenges.

GuruFocus.com last month

BPMC
-2.90%
Q4 2024 Blueprint Medicines Corp Earnings Call

Q4 2024 Blueprint Medicines Corp Earnings Call

Thomson Reuters StreetEvents last month

BPMC
-2.90%
Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -12.86% and 0.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

BPMC
-2.90%
Blueprint Medicines: Q4 Earnings Snapshot

The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of 70 cents per share. The cancer drug developer posted revenue of $146.4 million in the period, which also missed Street forecasts. Ten analysts surveyed by Zacks expected $147.5 million.

Associated Press Finance last month

BPMC
-2.90%
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results

Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2024 and provided financial guidance.

PR Newswire last month

BPMC
-2.90%
Earnings Preview: Axsome Therapeutics (AXSM) Q4 Earnings Expected to Decline

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

BPMC
-2.90%
Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

BPMC
-2.90%
INCY
Should You Buy Blueprint Medicines (BPMC) After Golden Cross?

Is it a good or bad thing when a stock experiences a golden cross technical event?

Zacks last month

BPMC
-2.90%
Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 13, 2025, to report its fourth quarter and full year 2024 financial results and provide a corporate update.

PR Newswire last month

BPMC
-2.90%
Why Blueprint Medical (BPMC) Is Skyrocketing Now

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Blueprint Medical (NASDAQ:BPMC) stands against the other stocks. Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a […]

Insider Monkey 2 months ago

BPMC
-2.90%

Performance Overview

Return	BPMC	S&P 500 (^GSPC)
YTD	-1.47%	-4.23%
1-Year	-10.87%	+7.42%
3-Year	+31.41%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Blueprint Medicines Corporation (BPMC)

Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference

Is Blueprint Medicines (BPMC) One of the Best Mid Cap Biotech Stocks to Buy?

Is Blueprint Medicines Corporation (BPMC) a Promising Biotech Stock According to Wall Street Analysts

Blueprint Medicines (BPMC): Among Stocks Insiders Are Selling In March

Reddit initiated, Netflix upgraded: Wall Street’s top analyst calls

Exploring High Growth Tech Stocks In The US Market March 2025

Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress

Blueprint Medicines Corporation (BPMC): Among the Oversold Biotech Stocks to Buy Now

Blueprint Medicines Full Year 2024 Earnings: EPS Beats Expectations

BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline

Blueprint Medicines Corp (BPMC) Q4 2024 Earnings Call Highlights: Record Growth and Strategic ...

Q4 2024 Blueprint Medicines Corp Earnings Call

Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates

Blueprint Medicines: Q4 Earnings Snapshot

Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results

Earnings Preview: Axsome Therapeutics (AXSM) Q4 Earnings Expected to Decline

Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know

Should You Buy Blueprint Medicines (BPMC) After Golden Cross?

Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Why Blueprint Medical (BPMC) Is Skyrocketing Now

Performance Overview